Clinical Scorecard: Innovative Approaches in the Management of Colorectal Cancer

At a Glance

Key Highlights

• Intraoperative intraperitoneal perfusion chemotherapy with raltitrexed during laparoscopic resection shows feasibility and potential to reduce peritoneal metastasis risk.
• Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (CRS + HIPEC) offers survival benefits in selected patients but requires careful patient selection and perioperative management.
• Targeted therapies combined with stereotactic body radiotherapy improve outcomes in pulmonary oligometastases from CRC, overcoming radioresistance.

Guideline-Based Recommendations

Diagnosis

• Utilize machine learning algorithms on routine blood tests to identify patients at high risk for liver metastasis for early detection and intervention.

Management

• Consider intraoperative intraperitoneal perfusion chemotherapy with raltitrexed as an adjunct during laparoscopic radical resection in high-risk patients.
• Employ cytoreductive surgery plus HIPEC for selected patients with peritoneal metastases in high-volume centers with experienced multidisciplinary teams.
• Integrate targeted agents such as cetuximab or bevacizumab with stereotactic body radiotherapy for pulmonary oligometastases to enhance local control and survival.

Monitoring & Follow-up

• Monitor carcinoembryonic antigen (CEA) levels postoperatively to assess response to intraperitoneal chemotherapy.
• Closely observe for surgical, anesthetic, and chemotherapy-related complications following CRS + HIPEC with rigorous perioperative protocols.

Risks

• Recognize significant morbidity associated with CRS + HIPEC necessitating meticulous patient selection and management.
• Be aware of potential adverse effects related to combined chemoradiotherapy and targeted therapies.

Patient & Prescribing Data

Patients with locally advanced CRC, peritoneal metastases, pulmonary oligometastases, and those at risk for liver metastases

Multimodal approaches combining surgery, intraperitoneal chemotherapy, targeted agents, and radiotherapy improve survival and local control; early detection via machine learning enhances timely treatment.

Clinical Best Practices

• Adopt multidisciplinary collaboration to personalize treatment plans integrating surgical, systemic, and radiotherapeutic modalities.
• Perform intraperitoneal chemotherapy intraoperatively in high-risk patients to reduce microscopic disease and peritoneal dissemination.
• Select patients carefully for CRS + HIPEC and manage in specialized high-volume centers to minimize morbidity.
• Combine targeted therapies with radiotherapy for oligometastatic disease to overcome resistance and improve outcomes.
• Implement machine learning-based predictive models using routine blood tests for early detection of metastases to guide timely interventions.

References

• Jin et al. - Intraoperative intraperitoneal perfusion chemotherapy with raltitrexed
• Karimi et al. - Cytoreductive surgery and HIPEC for peritoneal metastases
• Sun et al. - Targeted therapy combined with stereotactic body radiotherapy for pulmonary oligometastases
• Yu et al. - Machine learning for early detection of liver metastasis